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Biopsy of the kidney, liver, bone marrow and other organs is
routinely performed in clinical medicine. Endomyocardial
biopsy also has now become a routine diagnostic procedure
in many medical centers around the world. In 1962, the
Japanese team of Sakakibara and Konno (1) introduced
a bioptome for a transvenous approach to the heart. By
1970, the efficacy of this type of bioptome had been con-
clusively demonstrated and accepted in the Western world.
There have been many modifications of the original biop-
tome, as well as variations in technique for obtaining myo-
cardial biopsies, and the indications for endomyocardial
biopsy have increased. More recently, several of the biop-
tomes have been modified to include a pediatric bioptome,
which can be used for very young children including neo-
nates.
In this issue of the Journal, Yoshizato et al. (2) present an
updated review of the safety and utility of endomyocardial
biopsy in infants and children. Their study is of interest
because there are still relatively few reports regarding the
complications and results of endomyocardial biopsy in chil-
dren. Although their study includes children aged 2 months
to 20 years, the mean age of their 53 patients was 13 years;
25% of the patients were :510 years old. The importance of
their study, which is primarily a nontransplant diagnostic
endomyocardial biopsy study in children, is that it is also
applicable to the burgeoning heart transplantation setting. At
present, cardiac transplantation management relies heavily,
and almost exclusively on the morphologic index obtained
by endomyocardial biopsy for the diagnosis of acute rejec-
tion.
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From International Society of Heart Transplantation rec-
ords (3), the age group for cardiac transplantation and
combined heart-lung transplantation has been extended
to include neonates and very young children. Heart trans-
plantation in the youngest recipients was performed at
birth, and combined heart-lung transplantation has been
performed in children 3 months old. Between 1984 and 1988,
>65 children < 1month old received a cardiac transplant, as
did a total of233 children <10 years old received a transplant
(Fig. 1).
The present study. With the exponential rise in cardiac
transplantation in this country, it is clear that more and more
children will require endomyocardial biopsy. The study by
Yoshizato et al. (2) adds to our knowledge of such biopsies
by describing the results of 66 procedures in 53 children. It is
encouraging to note that the endomyocardial biopsies in this
group were either diagnostic or confirmatory in 67% to 96%.
It is also encouraging that 96% of the endomyocardial
biopsies were successful, and that a mean of five biopsy
specimens was obtained in each biopsy procedure, a number
that not only is adequate for diagnosis, but also is a satis-
factory number to minimize the sampling error inherent in
endomyocardial biopsy.
The authors (2) suggest that in two cases the biopsies
were not helpful, because "normal" tissue was obtained.
One can take the view that these normal biopsies are indeed
very helpful, because they rule out conditions that cause
hypertrophy and fibrosis or other conditions that are diffuse
in nature, such as hemochromatosis or metabolic storage
diseases. A related point is that attitude in examining small
pieces of myocardium is important. For example, one can
report nonspecific hypertrophy or one can observe that
hypertrophy in a small child confirms or "is consistent with"
the clinical suspicion of cardiomyopathy, which is the more
useful approach.
In discussing cardiomyopathy, the authors have stated
that "in most cases, biopsy tissues demonstrate myocyte
hypertrophy and interstitial fibrosis, thereby confirming a
diagnosis of cardiomyopathy; but these findings are nonspe-
cific and do not provide information concerning possible
causes of the disorder." However, no special studies were
performed and the use of electron microscopy was not
addressed. For example, in some cases offamilial cardiomy-
opathy (4), mitochondrial abnormalities may be seen, and
today it is also possible to study these small biopsy speci-
mens with new techniques, such as polymerase chain reac-
tion.
Diagnosis of myocarditis. The report by Yoshizato et al.
(2) raises the question of myocarditis and, once again,
confirms the poor correlation between the clinical and bi-
opsy diagnoses of acute myocarditis in infants, children and
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Figure 1. Age distribution in 233 child cardiac recip-
ients (1984 to 1988). (Modified from the International
Society of Heart Transplantation Registry.)
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adolescents. This finding supports the emerging awareness
that the clinical diagnosis of acute myocarditis is often not
confirmed morphologically. This discrepancy is not neces-
sarily a sampling error of the biopsy, but rather an indication
that there is indeed no acute myocarditis, and that it is being
mimicked clinically by cardiomyopathy or other conditions.
This possibility is borne out by the large number of trans-
plant patients with suspected acute myocarditis whose ex-
planted heart manifests the pathologic features of end-stage
cardiomyopathy of the dilated type. Sometimes there are
residual foci of lymphocytes, and there have been many
published discussions (5,6) as to the nature of these lympho-
cytes; although they may be residual from a previous epi-
sode of acute myocarditis, they probably do not represent
acute myocarditis at this stage. This is particularly true in
children, because a background of hypertrophy and fibrosis
would be totally inconsistent with acute myocarditis and, by
the time the hypertrophy and fibrosis are evident, the child
already has developed a cardiomyopathy, even though re-
sidual lymphocytes may be seen. Children dying of acute
myocarditis have florid interstitial infiltrates with myocyte
necrosis and usually no background hypertrophy and fi-
brosis. One would expect children presenting with heart
failure to have a florid, diffuse, rather than focal, inflamma-
tory infiltrate (although focal infiltrates could result in ar-
rhythmias).
Complications of endomyocardial biopsy. The question of
the morbidity of endomyocardial biopsy in children is im-
portant. Although the need for general anesthesia is not
addressed by Yoshizato et al. (2), it should be remembered
that infants and young children require general anesthesia to
obviate the possibility that air embolus might occur while
they are crying during the procedure. Anesthesia is an extra
hazard that is not necessary in older children or adults.
Serious complications in children are rare in other reported
series. At Stanford, there have been no cardiac perforations
in ZOO cardiac biopsies in children (unpublished data). In the
report by Yoshizato et al. (2), three cardiac perforations
were recorded, although in each case the outcome was good.
It is interesting to speculate whether this higher rate of
perforation might be due to the femoral approach used
exclusively by their group or to the type of bioptome used.
The more direct approach through the right internal jugular
vein with a size 5F or 6F bioptome might be safer in very
young children. This question still needs to be answered. It
should also be stated that these inva,sive studies should be
performed only by skilled and experienced invasive cardiol-
ogists or surgeons.
Conclusions. Endomyocardial biopsy has made possible
the earliest morphologic detection of cardiac disease in the
living patient, has allowed the evolution of the disease to
be followed and has documented its morphologic reversal
after a course of treatment. With the application of
new techniques of immunohistochemistry, ultrastructural
changes, gene rearrangement techniques and cardiac re-
ceptor studies to the diagnosis and treatment of cardio-
vascular disease, the potential role of endomyocardial bi-
opsy is greater. These advances can now be extended to the
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pediatric group of patients in whom endomyocardial biopsy
is possible.
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